Development of a novel biologic showing downregulation of immune responses, suppression of bone destruction and retention in the target site.

Research Project

Project/Area Number	16K15654
Research Category	Grant-in-Aid for Challenging Exploratory Research
Allocation Type	Multi-year Fund
Research Field	Orthopaedic surgery
Research Institution	The University of Tokyo
Principal Investigator	Honma Masashi 東京大学, 医学部附属病院, 講師 (60401072)
Project Period (FY)	2016-04-01 – 2018-03-31
Project Status	Completed (Fiscal Year 2017)
Budget Amount *help	¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000) Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000) Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywords	免疫学 / 骨代謝 / シグナル伝達 / 生理活性
Outline of Final Research Achievements	Outcomes of RA treatment are recently improved due to the development of various anti-inflammatory biologics, however; there remains insufficiency from the viewpoint of protection from the bone destruction and the rate of remission induction. In the present study, we constructed a novel biologic; a tandem fusion construct of CTLA-4 extracellular domain, IgG1 Fc domain and anti-RANKL scFv. Experimental treatment of collagen-induced arthritis mice model showed that this construct exhibited stronger suppression of articular inflammation and protection from cartilage and bone destruction compared to the existing biologic abatacept.

Report

(3 results)